- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01134692
Probiotics for Portal Hypertension
COMPARATIVE STUDY OF NORFLOXACIN AND PROBIOTICS ON PORTAL PRESSURE IN PATIENTS WITH CIRRHOSIS AND LARGE VARICES WHO HAVE NEVER BLED IN THE PAST
Chronic peripheral and splanchnic vasodilatation are the hallmark hemodynamic abnormality in cirrhosis and contribute to the pathogenesis of portal hypertension.
Alterations in intestinal motility and bacterial overgrowth in gut may predispose to the development of bacteraemia and endotoxaemia in cirrhotic patients which play a role in the hyperdynamic circulatory syndrome of cirrhosis. Probiotic therapy is aimed at changing the make-up of the indigenous microflora by administering specific strains of non-pathogenic and potentially beneficial microflora. In this study, the investigators hypothesize that a modification in the composition of the endogenous digestive microflora by oral bacteriotherapy with high potency probiotic preparations could be a safe way to regulate the portal pressure.
As there is a relative paucity in effective pharmacological treatment for portal hypertension, these novel and innovative therapy might provide important alternative or adjunct therapy to beta blockers in the clinical management of patients with portal hypertension.
Aims and objectives
To study in patients with cirrhosis and large varices whether probiotics and/or norfloxacin given for 2 months :
- achieve a reduction in HVPG
- alter the endotoxin and cytokine levels, and improve systemic inflammatory responses
- well tolerated.
Inclusion criteria:
Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:
- Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with or without liver biopsy)
- No history of upper GI bleeding in the past
- Endoscopically documented large esophageal varices
Exclusion criteria
- history of gastrointestinal bleeding
- patients who have received beta blockers for portal hypertension in the past 6 weeks.
- hepatic encephalopathy
- ongoing bacterial infection,
- Spontaneous bacterial peritonitis
- active alcoholism or illicit drug abuse
- alcoholic hepatitis
- Treatment with antibiotics in the preceding 2 weeks.
- presence of hepatocellular carcinoma,
- portal vein thrombosis
- serum creatinine>1.5 mg/dL,
- treatment with vasoactive drugs in the past 6 weeks,
- history of arterial hypertension, congestive heart failure or arterial occlusive disease, and
- Refusal to participate.
- Active smokers.
Study plan:
Ethical approval will be obtained prior to study initiation. Patients presenting to Department of Gastroenterology, GB Pant Hospital will be recruited in the study. Patients will be evaluated regarding the eligibility for the study. After being found eligible for the study, if the patient agrees to participate in the study, a signed informed consent will be obtained. Baseline HVPG will be measured in all patients and then they will be randomized into 3 groups:.
- Group 1: Beta blockers + placebo
- Group 2: Beta blockers + Norfloxacin (400mg BD)
- Group 3: Beta blockers + probiotics. (one sachet of VSL#3 BD)
30 patients will be enrolled into each group. The treatment will be continued for 2 months.
The study design is a randomized double-blinded placebo controlled trial.
Once patients have been enrolled, they will undergo baseline investigations. Blood will be drawn from both peripheral and hepatic veins and sent for routine parameters, pro-inflammatory cytokines (IL-1b, IL-6, IL-10, TNF-α, endotoxins, NO2 and NO3 levels, PRA, BNP). Samples will be stored at -70 ºC. Baseline vitals will be recorded.
Patients will be called at the end of 1 month for assessment of compliance and then at the end of the study (2 months) to repeat the HVPG and the same parameters as at the time of enrollment
End Points:
Primary
a. Change in HVPG levels as compared with baseline, to define responder (≥20% reduction in HVPG or ≤ 12 mm Hg).
Secondary
- Change in digestive flora
- Reduction in serum and hepatic endotoxin and cytokine levels
- Assessment of improvement in the renal parameters and Systemic inflammatory response syndrome
- Improvement in the markers of oxidative injury
- Adverse effects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Nitin Gupta, MD
- Phone Number: +919718599209
- Email: drnitingupta_id@rediffmail.com
Study Locations
-
-
-
Delhi, India, 110002
- Recruiting
- GB Pant Hospital
-
Contact:
- Nitin Gupta, MD
- Phone Number: +919718599209
- Email: drnitingupta_id@rediffmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Consecutive patients of cirrhosis with portal hypertension who fulfill the following criteria:
- Diagnosed cases of cirrhosis (by clinical, biochemical and radiological criteria with or without liver biopsy)
- No history of upper GI bleeding in the past
- Endoscopically documented large esophageal varices
Exclusion Criteria:
- history of gastrointestinal bleeding
- patients who have received beta blockers for portal hypertension in the past 6 weeks.
- hepatic encephalopathy
- ongoing bacterial infection,
- Spontaneous bacterial peritonitis
- active alcoholism or illicit drug abuse
- alcoholic hepatitis
- Treatment with antibiotics in the preceding 2 weeks.
- presence of hepatocellular carcinoma,
- portal vein thrombosis
- serum creatinine>1.5 mg/dL,
- treatment with vasoactive drugs in the past 6 weeks,
- history of arterial hypertension, congestive heart failure or arterial occlusive disease, and
- Refusal to participate.
- Active smokers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Propranolol + Placebo
|
Propranolol: as per heart rate titration Norfloxacin: 400mg BD
|
ACTIVE_COMPARATOR: Propranolol + Norfloxacin
drug
|
Propranolol: as per heart rate titration Norfloxacin: 400mg BD
|
EXPERIMENTAL: Propranolol + Probiotic
VSL#3
|
Propranolol: as per heart rate titration Norfloxacin: 400mg BD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in HVPG levels as compared with baseline, to define responder (≥20% reduction in HVPG or ≤ 12 mm Hg).
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse effects
Time Frame: 2 months
|
2 months
|
Assessment of improvement in the renal parameters and Systemic inflammatory response syndrome
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Liver Diseases
- Esophageal Diseases
- Hypertension, Portal
- Fibrosis
- Liver Cirrhosis
- Esophageal and Gastric Varices
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors
- Propranolol
- Norfloxacin
Other Study ID Numbers
- NG002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
University Health Network, TorontoUnknown
-
National Institute of Diabetes and Digestive and...National Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
Northwestern UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Cancer... and other collaboratorsRecruitingCirrhosis | Cirrhosis, Liver | Cirrhosis Due to Hepatitis B | Cirrhosis Due to Hepatitis C | Cirrhosis Early | Cirrhosis Advanced | Cirrhosis Infectious | Cirrhosis Alcoholic | Cirrhosis, Biliary | Cirrhosis Cryptogenic | Cirrhosis Due to Primary Sclerosing CholangitisUnited States
-
RenJi HospitalNot yet recruiting
-
Nanfang Hospital, Southern Medical UniversityRecruiting
-
Institute of Liver and Biliary Sciences, IndiaRecruiting
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
Clinical Trials on Propranolol, Norfloxacin, VSL#3
-
Dayton Children's HospitalNational Institutes of Health (NIH)TerminatedIrritable Bowel SyndromeUnited States
-
Policlinico HospitalUnknown
-
University of Maryland, BaltimoreNational Center for Complementary and Integrative Health (NCCIH)Terminated
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Recruiting
-
Bambino Gesù Hospital and Research InstituteCompleted
-
Policlinico HospitalCompleted
-
Beth Israel Deaconess Medical CenterTerminated
-
Federico II UniversityUnknown
-
Kaplan-Harzfeld Medical CenterCompletedConstipation | Diarrhea
-
Elena Pita CalandreFerring Pharmaceuticals; Actial Farmaceutica S.r.l.CompletedFibromyalgia | Gastrointestinal DiseaseSpain